New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 20, 2013
05:26 EDTTEVA, GILDGilead, Teva reach settlement agreement in Viread patent litigation
Gilead Sciences (GILD) announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread, a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.
News For GILD;TEVA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
January 20, 2015
10:40 EDTTEVAMomenta Pharma sinks after Supreme Court rules on Copaxone
Subscribe for More Information
10:35 EDTTEVATeva rises after patent ruling upheld by Supreme Court
The Supreme Court upheld a lower court ruling related to generic versions of Teva's Copaxone drug. In the ruling, the court wrote that "When reviewing a district court’s resolution of subsidiary factual matters made in the course of its construction of a patent claim, the Federal Circuit must apply a “clear error,” not a de novo, standard of review." Teva shares are up 1.5% to $58.58 in early trading after the ruling. Reference Link
09:38 EDTGILDActive equity options trading
Subscribe for More Information
January 16, 2015
14:54 EDTGILDGilead at high of day, up 3% after reaching hep C drug pact with Aetna
14:46 EDTGILDAetna, Gilead confirm discount pricing for hepatitis C drugs Harvoni, Sovaldi
Subscribe for More Information
13:05 EDTGILDGilead granted orphan status for pulmonary arterial hypertension treatment
The FDA granted Gilead orphan status for its treatment of pulmonary arterial hypertension. Reference Link
09:37 EDTGILDActive equity options trading
Subscribe for More Information
January 15, 2015
11:20 EDTGILDGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
January 14, 2015
09:36 EDTGILDActive equity options trading
Subscribe for More Information
07:08 EDTGILDGilead still poised to beat 2015 estimates, says RBC Capital
Subscribe for More Information
January 13, 2015
16:00 EDTGILDOptions Update; January 13, 2015
iPath S&P 500 VIX Short-Term Futures up 66c to 34.42. Option volume leaders: AAPL JNJ CELG WFM TSLA TWTR AMZN GILD according to Track Data.
12:15 EDTGILDExpress Scripts CEO says Gilead relationship 'important' going forward
Express Scripts (ESRX) CEO George Paz at the J.P. Morgan Healthcare Conference said his company's relationship with Gilead (GILD) is "important" going forward. Paz said his company's goal is not to exclude drugs. He continues to discuss Express Scripts's deal with AbbVie (ABBV) and the company's goal of saving clients money with regards to healthcare costs.
12:10 EDTGILDExpress Scripts CEO says 'never stopped talking to Gilead'
Subscribe for More Information
11:43 EDTGILDGilead says negotiations ongoing with major U.S. payors for Harvoni
Subscribe for More Information
11:10 EDTGILDGilead drops, levels to watch
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL AMD AA TWTR GILD C CELG TSLA GOOG
07:42 EDTGILDJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link
January 12, 2015
09:35 EDTTEVATeva may need to jump back into M&A after quiet 2014, Bloomberg says
Teva (TEVA), one of few leading pharmaceutical makers that did not make a sizable acquisition in 2014, may need to catch up with peers in that regard, with Perrigo (PRGO) and Sweden’s Meda AB mentioned by analysts as potentially suitable targets, said Bloomberg's "Real M&A" column. Reference Link
09:34 EDTGILDActive equity options trading
Subscribe for More Information
08:31 EDTTEVAAMRI announces the departure of CFO Michael Nolan
AMRI announced that Michael Nolan, senior vice president and CFO, will be departing AMRI. Nolan will remain with AMRI through February 2015 to support an orderly transition. The company also announced that Felicia Ladin will join the company in the same role, effective February 4, 2015. Ladin most recently served as Senior Vice President, CFO, Global Specialty Medicines at Teva (TEVA).
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use